H1B Report
Side-by-side comparison

INFOSYS LIMITED vs Mylan Pharmaceuticals, Inc.

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
INFOSYS LIMITED
TXRank #1FEIN 58-1760235
Entity B
Mylan Pharmaceuticals, Inc.
PARank #FEIN 55-0455423

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricINFOSYS LIMITEDMylan Pharmaceuticals, Inc.
Total filings200,329132
Certified %99.55%79.55%
Denied %0.21%1.52%
Withdrawn %0.20%2.27%
Cert-withdrawn %0.05%16.67%
Rank#1
Active yearsFY2010–FY2026FY2010–FY2025
Worksite stateTXPA

Outcomes — INFOSYS LIMITED

DOL case-status mix.

Outcome breakdown: Certified 99.5%, Cert-withdrawn 0.0%, Withdrawn 0.2%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%

Outcomes — Mylan Pharmaceuticals, Inc.

DOL case-status mix.

Outcome breakdown: Certified 79.5%, Cert-withdrawn 16.7%, Withdrawn 2.3%, Denied 1.5%
Outcome breakdown
OutcomeShare
Certified79.5%
Cert-withdrawn16.7%
Withdrawn2.3%
Denied1.5%
Certified79.5%
Cert-withdrawn16.7%
Withdrawn2.3%
Denied1.5%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

INFOSYS LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,138
FY20111,681
FY201214,633
FY201331,994
FY201423,467
FY201532,976
FY201624,049
FY201720,254
FY201811,519
FY201921,102
FY202016
FY202129
FY202222
FY20232,269
FY20245,943
FY20255,790
FY20262,447
Mylan Pharmaceuticals, Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20104
FY201111
FY20126
FY201314
FY201417
FY201514
FY201620
FY201712
FY201815
FY201913
FY20200
FY20211
FY20220
FY20231
FY20241
FY20253
FY20260

Top 5 occupations — INFOSYS LIMITED

Top 5 occupations — Mylan Pharmaceuticals, Inc.

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.